In today’s financial landscape, Blue Jet Healthcare Limited has embarked on its highly anticipated journey into the world of Initial Public Offerings (IPOs). This article is your comprehensive guide to the Blue Jet Healthcare IPO, featuring an in-depth analysis, key dates, and expert insights. Blue Jet Healthcare IPO Overview The Blue Jet Healthcare  IPO has […]
Blue Jet Healthcare IPO

In today’s financial landscape, Blue Jet Healthcare Limited has embarked on its highly anticipated journey into the world of Initial Public Offerings (IPOs). This article is your comprehensive guide to the Blue Jet Healthcare IPO, featuring an in-depth analysis, key dates, and expert insights.

Blue Jet Healthcare IPO Overview

The Blue Jet Healthcare  IPO has officially opened for subscription and will continue to welcome bids until the 27th of October, 2023. If you’re considering participating, the window for applying spans from Wednesday to Friday this week. The company has established an IPO price range of ₹329 to ₹346 per equity share, and it’s poised for listing on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).

Intriguingly, the shares of Blue Jet Healthcare Limited have already made a remarkable entrance into the grey market. As of today, market observers have reported a significant premium of ₹85 per share in the grey market.

Blue Jet Healthcare  IPO Subscription Status

As of 11:57 AM on the first day of bidding, the Blue Jet  Health care IPO has been subscribed approximately 0.20 times in the public offering, while the retail portion boasts a subscription rate of 0.30 times. Simultaneously, the Non-Institutional Investors (NII) segment of the book build issue has reached a subscription rate of 0.25 times.

Essential Blue Jet Healthcare IPO Details

  • Blue Jet  Health care IPO GMP: Market observers have noted a substantial premium of ₹85 per share for Blue Jet Healthcare in the grey market today.
  • Blue Jet Health care IPO Date: Bidding for this promising IPO will remain open from the 25th to the 27th of October 2023.
  • Blue Jet Health care IPO Price: The company has set the issue price at ₹329 to ₹346 per equity share.
  • Blue Jet Health care IPO Size: Blue Jet Healthcare aims to raise ₹840.27 crore through a complete offer for sale (OFS).
  • Blue Jet Health care IPO Lot Size: Investors have the opportunity to apply for this IPO in lots, with each lot consisting of 43 company shares.
  • Blue Jet Health care IPO Allotment Date: The expected date for finalizing share allocations is the 1st of November 2023.
  • Blue Jet Health care IPO Registrar: Link Intime India Private Ltd has been appointed as the official registrar for this public offering.
  • Blue Jet Health care IPO Listing: The book build issue is proposed for listing on both BSE and NSE.
  • Blue Jet Health care IPO Listing Date: The anticipated date for the listing of shares is the 6th of November 2023.

Expert Opinions on Blue Jet Healthcare IPO

As you contemplate your investment decision, it’s important to consider the expert opinions surrounding the Blue Jet Health care IPO. Choice Broking, for instance, emphasizes the company’s core operations as a Contract Development and Manufacturing Organization (CDMO), generating around 75% of its business from CDMO activities. With a niche product profile and long-lasting client relationships, they note that around 70% of the total business derives from long-term contracts. Despite some challenges with higher raw material costs, the company maintained a healthy Return on Equity (RoE), even with a 3x rise in net worth. Going forward, Blue Jet Health care is poised for growth, with plans for brownfield and greenfield expansions that will increase capacity by approximately 50% by FY25. In conclusion, the report suggests that the Blue Jet Health care IPO presents robust growth prospects and a comfortable valuation, making it a suitable option for potential subscribers.

Reliance Securities also advocates for subscribing to the IPO, highlighting Blue Jet Health care as an innovative company with more than two decades of experience and specialized chemistry capabilities. Their strategic approach involves diversifying revenues and a focus on high-margin products. With expansion plans on the horizon, they anticipate increased demand and higher earnings in the coming years.

Please note that these recommendations come from individual analysts and broking companies, and not from Foundr Magazine. It is advisable to seek advice from certified experts before making any investment decisions.